Tracking COVID-19 Agreements

A Worldwide Response

The COVID-19 pandemic has highlighted the need for all decision makers to be able to rapidly translate policies on key issues into practical agreement language. The challenges associated with COVID-19 related agreements are leading to expansion and adaptation of traditional approaches used to address issues facing the formation of alliances, including ownership of IP and transparency. GHIAA is tracking the formation of alliances and agreements related to the development of diagnostics, therapeutics and vaccines for COVID-19. We intend to provide analysis of the agreements in the GHIAA MAPGuide as they become available.

Please note: the contents of the tables provided on this page are formed from GHIAA’s understanding and interpretation of publicly available information. The purpose of creating these tables is to begin to identify agreements related to the COVID-19 response. We endeavour to update the tables regularly, however they should not be relied upon to provide a complete overview of the current landscape.

A Worldwide Crisis

The COVID-19 pandemic has highlighted the need for all decision makers to be able to rapidly translate policies on key issues into practical agreement language. The challenges associated with COVID-19 related agreements are leading to expansion and adaptation of traditional approaches used to address issues facing the formation of alliances, including ownership of IP and transparency. GHIAA is tracking the formation of alliances and agreements related to 

the development of diagnostics, therapeutics and vaccines for COVID-19. We intend to provide analysis of the agreements in the GHIAA MAPGuide as they become available.

Please note: the contents of the tables provided on this page are formed from GHIAA’s understanding and interpretation of publicly available information. The purpose of creating these tables is to begin to identify agreements related to the COVID-19 response. We endeavour to update the tables regularly, however they should not be relied upon to provide a complete overview of the current landscape.

Diagnostics

Click on the Learn More button below to download a PDF summary of COVID-19 diagnostics in development, and the related agreements, partnerships and alliances.

Therapeutics

Click on the Learn More button below to download a PDF summary of COVID-19 therapeutics in development, and the related agreements, partnerships and alliances.

Vaccines

Click on the Learn More button below to download a PDF summary of COVID-19 vaccine candidates, and the related agreements, partnerships and alliances.

Useful Articles

  • Nicholson Price II, Arti K. Rai, Timo Minssen, Knowledge transfer for large-scale vaccine manufacturing, Science (21 August 2020) – article about the importance of knowledge transfer in facilitating manufacturing scale-up.
  • Adam Houldsworth, New IP policy to help forge partnerships on potential UK covid-19 vaccine, IAM (April 16, 2020) – article explaining expedited access to Oxford’s IP during the COVID-19 pandemic.
  • Francis Gurry, Some Considerations on Intellectual Property, Innovation, Access and COVID-19, WIPO (Apr. 24, 2020) – article arguing that the main challenge at the present time is not access to vaccines, treatments or cures for COVID-19, but the absence of any approved vaccines, treatments or cures to have access to.
  • Fred Reinhart, Exercising Bayh-Dole march-in rights would handicap Covid-19 innovation, STAT (May 4, 2020) – article arguing that using march in rights for price control is harmful and stifles innovation by discouraging investment
  • Zachary Brennan & Dan Goldberg, Coronavirus Drugmakers’ Latest Tactics: Science by Press Release, Politico (June 8, 2020) – article arguing that press releases are creating hype and political pressure on government actors that could lead to less than scientific vaccine approvals.
  • Lev Facher, Trump administration pledges future Covid-19 vaccines will be free for ‘vulnerable’ Americans, STAT (June 16, 2020) – article about the Trump administration pledge to provide a future Covid-19 vaccine for free to “vulnerable” Americans unable to afford it.
  • Sonia Pagliusi et al., Emerging Manufacturers engagements in the COVID -19 vaccine research, development and supply, Vaccine Journal (June 11, 2020) – an analysis of DCVMN members’ manufacturing capacity, concluding that there will likely be adequate capacity.
  • World Health Organization, A Global Framework to Ensure Equitable and Fair Allocation of COVID-19 Products and Potential Implications for COVID-19 Vaccines (June 18, 2020) – a proposal for vaccine distribution providing that the 3 groups that should get priority are: health care workers, adults older than 65, and adults with comorbidities such as cancer, cardiovascular disease, and obesity.
  • EMA press office The ACCESS (vACcine Covid-19 monitoring readinESS) project (May 27, 2020) – press release regarding an agreement between the European Medicines Agency & Utrecht University to conduct preparatory research into data sources and methods that can be used to monitor the safety, effectiveness and coverage of COVID-19 vaccines in clinical practice.
  • Francis S. Collins, Paul Stoffels, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times, JAMA (May 18, 2020) article about an NIH-led public-private partnership focused on accelerating the development and deployment of COVID-19 therapeutics and vaccines.
  • FDA, Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry (June 2020) – industry guidance document from the U.S. Food & Drug Administration.
  • Access to Medicine Foundation, Will COVID-19 harm or help pharma’s access to medicine efforts, asks 2021 Access to Medicine Index (10 July 2020) – article highlighting that the 2021 Access to Medicine Index will capture pharmaceutical company response to COVID-19, including safeguarding of access-to-medicine programs.